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Paget-Schroetter syndrome treated with
thrombolytics and immediate surgery
J. Ernesto Molina, MD, PhD,a David W. Hunter, MD,b and Charles A. Dietz, MD,b Minneapolis, Minn
Introduction:Reviewed are the results of the emergent treatment of effort thrombosis of the subclavian vein. The protocol
calls for immediate thrombolysis, followed by surgery at the time of the acute event. The one-stage procedure includes
decompression of the thoracic inlet by subclavicular removal of the first rib, subclavius muscle, scalenectomy, and vein
patch plasty of the stenotic segment of the vein.
Methods: Between July 1985 through June 2006, 114 patients presented with Paget-Schroetter syndrome (effort
thrombosis of the subclavian vein), 97 of which (group I) were seen<2 weeks of onset of symptoms. They underwent an
emergent protocol treatment in which thrombolysis is immediately followed by surgery at the time of the acute event. In
addition, another 17 patients (group II) were referred to our institution after being treated elsewhere with initial
thrombolysis, but with surgery deferred a mean 34 days (range, 2 weeks to 3 months) after the initial event. All patients
underwent the same lytic and surgical protocol. Operability was determined by the findings on the venogram. Routine
postoperative anticoagulation for 8 weeks was implemented with warfarin and clopidogrel.
Results: There was 100% success in re-establishing the flow and normal caliber of the subclavian vein in the 97 patients in
group I. Seven patients showed some residual stenosis that required balloon plasty and implant of a stent. Postoperative
duplex ultrasound imaging documented patency in all 97 patients (100%). The 17 patients with delayed surgery (group
II) showed progression of the fibrosis, with vein obstruction in 12 (70%). Only five patients (29%) were operable with
successful results. The remaining 12 patients were inoperable owing to extensive fibrosis and occlusion of the inflow, and
all 12 have remained disabled for the use of their arm.
Conclusions: The emergent approach to treat Paget-Schroetter syndrome seems to render the optimal results, with 100%
effectiveness in re-establishing venous flow and normal caliber to the vessel. When properly conducted, this operation
avoids the use of stents or balloon plasty with excellent long-term results, leaving the patients unrestricted for physical
activities. ( J Vasc Surg 2007;45:328-34.)Acute thrombosis of subclavian-axillary vein complex
constitutes Paget-Schroetter syndrome, named after the
two initial investigators in England and Austria who inde-
pendently described this entity.1,2 Usually, acute thrombo-
sis of the subclavian vein is associated with physical effort
done with the arms andmostly affects young people in their
productive years. If the appropriate treatment is not applied
early enough, the syndrome can evolve very rapidly into a
chronic stage with irreversible fibrotic changes of the vein
that may lead to its total obliteration with resulting chronic
edema and disability.
How the syndrome occurs is fairly well understood, yet
diverse opinions persist on what should be done immedi-
ately and which type of treatment should be implemented.3-7
Early attempts to effectively treat this condition were re-
ported by Hughes,1 Drapanas and Curran,8 Adams et al,9
Adams and DeWeese,10 and other pioneers. Even at that
time, the opinion was that emergent treatment should be
undertaken to re-establish the normal flow and caliber of
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328the vein and to prevent the chronic sequelae that develop
very rapidly.
In 1985, our protocol was designed and implemented
to approach this syndrome as an emergent situation, as
proposed by Adams et al,9 Drapanas and Curran,8 and Aziz
et al.3 Currently, thrombolytic therapy has become the
standard of care as the first step in treating this syndrome.
The interventional radiologist accomplishes this by using a
catheter-directed infusion technique of the drug until the
clot is dissolved. The next step is to decide the proper
approach to achieve the best results in treating effectively
the syndrome to prevent its recurrence. There are currently
two issues at hand: one is the need to decompress the
thoracic inlet, and the second is what to do with the
stenosed vein and when.
In recent years with the advent of percutaneous tech-
niques, options such as dilation and placement of stents in
the subclavian vein need to be addressed. We know now
that placement of stents in the subclavian vein without
previously decompressing the thoracic inlet leads to
crushed stents and total obliteration of the vessel.11-13
Although there is no disagreement on the need for
decompression of the thoracic inlet, the direct intervention
on the vein to re-establish its normal caliber has recently
become a matter of discussion owing to the current options
available: balloon angioplasty alone, either intraoperatively
as proposed by Schneider et al14 or in the postoperative
period entailing a second intervention with stent implant as
reported by Hall et al15 and Kreienberg et al.16 These
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doing inlet decompression, a simple venotomy, and patch
enlargement of the vein, as our standard protocol calls for,
all done in one single operation.
The other still current issue is the timing for the surgical
decompression after thrombolysis of the clot. Although the
work by Kunkel and Machleder17 was developed almost at
the same time as our protocol, they initially believed that
any operation to decompress the inlet needed to be done
weeks or months later, after the period of inflammation had
passed. This was contrary to the ideas of Hughes,1 Adams
et al,9 Drapanas and Curran,8 and other pioneers who had
advised immediate surgery years earlier and also contrary to
our concepts. We used the recommendations for an emer-
gent approach to designed our protocol and have contin-
ued applying it unchanged up to the present time. Our
experience implementing this method5,6 is the purpose of
our present report.
PATIENTS AND METHODS
Patient population. There were 114 patients seen
during a 21-year period, from July 1985 through April
2006. The mean patient age was 29.7 4.57 years (range,
16 to 47 years), and 66 (58%) were men and 48 (42%) were
women. The right arm was more frequently involved (75%)
than the left (25%), and most of the patients were right-
handed in doing their work or sports activity. Their occu-
pations were of a wide variety of sport activities such as
climbing, baseball pitching, swimming, tennis, and weight
lifting, as well as industrial occupations such as trash collec-
tors, mechanics, electricians, and others.
There were two categories of patients: group 1 con-
sisted of patients who we saw 2 weeks of the onset of
symptoms, and group II consisted of patients who came to
us 2 weeks to 3 months after the original event. Both
groups were acutely treated with catheter-directed throm-
bolysis during the initial episode, but in group II, the
treating physician followed the policy of keeping them on
anticoagulant (warfarin) during the waiting period before
referring them for surgical evaluation.
Methods of treatment. In group I, 97 patients were
seen a mean of 5.6 days (range, 1 to 14 days) after the onset
of symptoms. They immediately underwent our emergent
protocol, consisting of catheter directed-thrombolysis, fol-
lowed by surgical intervention. This entailed thoracic inlet
decompression (subclavicular resection of the first rib, sub-
clavius muscle resection, scalenectomy) and, in the same
session, vein patch angioplasty of the subclavian vein using
saphenous vein to restore its normal caliber. They were
anticoagulated postoperatively for 8 weeks.
Group II consisted of 17 patients who also underwent
catheter-directed thrombolysis initially but were evaluated
for surgery a mean of 34 days later (range, 2 weeks to 3
months). At the time of surgical evaluation, they all under-
went venography first and received a second catheter-
directed thrombolytic infusion to dissolve any possible clot
that might have formed during the waiting period. At the
end of this second thrombolysis, only patients with aninflow axillary vein 1 cm in diameter were considered
candidates for the operation. The surgical intervention in
these patients was exactly as in group I, followed by the
same 8 weeks of anticoagulation.
Emergent protocol. As soon as the patient arrived
and the diagnosis was made with the help of duplex ultra-
sound, we obtained a venogram to assess the extent of vein
obstruction. Thrombolytic therapy was started immedi-
ately by percutaneously placing an infusion catheter directly
in the thrombus and infusing the thrombolytic agent with
an electrical pump. This stage of the treatment was started
by the interventional radiologist, who positioned the cath-
eter properly, and then the surgeon monitored the fibrin-
ogen levels and the adequacy of the infusion as well as the
general care of the patient. The progression of the lytic
process was evaluated every 8 to 12 hours by obtaining
repeat venograms andmoving the catheter according to the
area where some thrombus was still present. No suction
devices or mechanical thrombectomy was used.
Once the thrombus was dissolved, the venogram
showed the extent of the fibrotic obstruction of the vein.
Fibrous stricture was always present (Fig 1). The length of
the stenosis was measured on the venogram. As soon as the
vein was cleared of thrombus, the thrombolytic therapy was
discontinued. The patient was switched to a low-intensity
(partial thromboplastin time [PTT], 45 to 65) heparin
infusion and the standard operation was undertaken. Hep-
arin was stopped 2 hours before the actual time of the
operation.
Thrombolytic therapy. Until May 1999, urokinase
was used by catheter-directed infusion in 62 patients. The
dose was 2200 U/(kg · h), which averaged 150,000 units
per hour. This dose proved very safe and prevented systemic
lytic effects. After May 1999, when urokinase was removed
from the market by the US Food andDrug Administration,
we switched to tenecteplase (TNK; Genentech, South San
Francisco, Calif), whichwas used in 39 patients at the infusion
Fig 1. The fibrous stricture of the subclavian vein is clearly visu-
alized after 1 hour of thrombolytic therapy.dose of 0.05mg/(kg · h), which averaged 0.25mg/h. In 13
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at the same dose of 0.05 mg/(kg · h), which averaged
0.25 mg/hour. Tenecteplase has been very effective and
very safe throughout these past 7 years. In addition, it is
affordable.
For our patients in this series, the only monitoring test
during thrombolytic infusion was measurement of fibrino-
gen by the Clauss method. Once the infusion was underway,
the fibrinogen level was not allowed to drift to0.15 g % to
prevent bleeding. We opted not to measure fibrinogen split
products or use other, more complicated tests, because
these results cannot be reported 30 minutes (as with the
fibrinogen levels) and thus have no practical applicability
for the conduct of our protocol.
Simultaneously with the thrombolytic infusion, intra-
venous heparin, preferably in the opposite arm, was admin-
istered at the rate of 500 U/h. As soon as the thrombolytic
infusion was completed, the heparin infusion was increased
to 1000 to 1200 U/h (low-intensity protocol), depending
on the patient’s size, until the time of surgery. In addition,
routine basic tests were obtained before beginning the
heparin, including international normalized ratio (INR),
PTT, platelet count, and thrombin time.
Surgical technique. The standard operation, which
has been previously described in detail,5,6,18-20 involved
exclusively an anterior subclavicular partial resection of the
anterior half of the first rib, removal of the subclavius
tendon, division of the anterior scalene tendon, part of the
middle scalene muscle to the level of the subclavian artery,
and vein patch plasty of the subclavian vein stenotic seg-
ment; for this we used a short piece of saphenous vein
harvested from the upper thigh to obtain greater diameter.
The procedure was done extrapleurally.
No anticoagulation was administered during the pro-
cedure while the first rib, the subclavius muscle, and the
scalene muscles were removed. Once the vein was com-
pletely isolated and ready for clamping and opening, a
bolus of heparin (100 U/kg) was given intravenously. At
Fig 2. With the subclavian vein freed and fully mobilized, an
incision (arrows) is placed across the stricture, extending medially
into the normal innominate vein.the same time, to prevent platelet aggregation, a bolus oflow-molecular-weight (40,000 wt) dextran (Rheomacro-
dex, Abbott Laboratories, North Chicago, Ill) in saline
solution was administered (50 mL) by anesthesia; dextran
was then continued at the rate of 15 mL/h without inter-
ruption.
After the vein was open (Fig 2), all the fibrous tissue
and the organized thrombus were removed (Fig 3). The
vein patch was laid over the venotomy (Fig 4), the clamps
were released, and the operation was completed. An ex-
trapleural drain (Jackson-Pratt #19 round, Cardinal
Health, McGaw Park, Ill) was left in place for 48 to 72
hours until the total amount of drainage per 24-hour
period was30 mL. Antibiotics were only used during the
time of surgery and for 48 hours postoperatively, until the
drain in the extrapleural space was removed.
Postoperatively, dextran was continued at the same rate
(15 mL/h) for the following 48 hours. That same evening
after the operation, warfarin (Coumadin, Bristol-Myers
Squibb, New York, NY) was administered at 10 mg orally
Fig 3. All of the organized fibrotic material causing the obstruc-
tion is removed before placement of the venous patch.
Fig 4. The saphenous vein patch is laid over the strictured seg-
ment of the vein.and then continued daily according to the INR. Also that
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was administered at 40mg subcutaneously, and since 1996,
clopidogrel (Plavix, Apotex, Weston, Ontario, Canada) at
75 mg orally. From 1985 through 1996, dipyridamole
(Persantin, Boerhinger-Ingelheim GmbH, Ingelheim,
Germany) was used instead as an antiplatelet agent at 50
mg orally, thrice daily. Bed rest continued for 24 hours.
Pain control was achieved through an intravenous patient
control analgesia system. The next morning, the patient’s
INR was monitored (usually anticoagulation does not
reach the therapeutic level of 2 to 3 until the second day
after surgery).
Enoxaparin and the Rheomacrodex were discontinued
at 48 hours; from that point on, only clopidogrel was
administered at the same dose of 75 mg daily and warfarin
was adjusted as necessary to keep the INR at 2 to 3. The
mean hospital stay was 4.3 days (range, 3.5 to 6 days; until
the desired level of anticoagulation was reached).
For long-term anticoagulation, we used warfarin to
maintain the INR at 2 to 3 and clopidogrel at 75 mg daily.
The total time on anticoagulants was 8 weeks, after which
the patient was taken off of all anticoagulation therapy. The
patient was considered cured when symptom free, fully
active, and with normal caliber and flow of the subclavian
vein verified on duplex ultrasound imaging.
If the length of the vein obliteration was 2 cm (usu-
ally 4 or 5 cm) and no normal innominate vein could be
reached from the subclavicular approach, then the surgical
incision was modified. This consisted in extending it medi-
ally into the sternum up to the midline and then angling
90° up towards the sternal notch (Fig 5). The detailed
technique has been described previously in relation to
chronic obstructions of the vein.15,16
If the standard incision is extended into the sternum
(transmanubrial incision), the patient’s arm needs to be
immobilized postoperatively with a sling for a minimum of
6 weeks and in some cases, 8 weeks. This is a very important
point to prevent dehiscence of the sternotomy, which will
Fig 5. Drawing shows the transmanubrial extension of the sub-
clavicular incision to the center of the sternum and vertically up to
the sternal notch. This exposes the entire subclavian (Scl) and
innominate vein without a need to remove or divide the clavicle.occur if the patient is allowed free use of the arm immedi-ately after surgery. The divided portion of the manubrium
is being held to the body of the sternum with only two wire
stitches,18-20 and they will not prevent dehiscence if the
patient is allowed to move the arm freely without any
restrictions.
Follow-up. The follow-up consisted in clinic visits at 2
and 6 weeks. Duplex ultrasound scans were obtained at 1
week and at 2, 6, and 12 months to verify the patency,
velocity of flow, pulsatility, and diameter of the vein. These
exams took place either at our institution or at the patient’s
place of origin, with the study evaluated by us. In 14
patients whose results were unclear, venography was nec-
essary, particularly when the stenosis was preoperatively
measured as 2 cm.
RESULTS
Monitoring fibrinogen levels showed that these were
quite high before the therapy was undertaken. Levels of 0.7
g/L% to 0.8 g/L% were not unusual. The levels during
thrombolysis never reached the 0.15 g/L% preset low limit.
Themean time to obtain total lysis was 6.6 hours (range, 90
minutes to 20 hours). No bleeding episodes occurred
during that time. Surgery was performed amean 3 hours 40
minutes (range, 2 to 14 hours) after completion of lysis.
Degree of obstruction. Once the thrombolytic infu-
sion was completed and all fresh clot was dissolved, we
assessed the length of the stenosis. In 85 patients (87%) of
group I, we identified a short segment (2 cm long)
resembling an hourglass figure. In 12 patients (13%), we
identified a long segment of stenosis (2 cm) with only a
narrow recanalized channel. The 17 patients in group II
who had been referred to surgery late in the course of the
syndrome all had long obstructions (2 cm) and a very
small amount of fresh thrombus that could be lysed. Nev-
ertheless, thrombolysis was always attempted to determine
operability of these patients.
Implementing our emergent protocol gave excellent
results to those 97 patients in group I. At both short-term
and mean long-term follow-up of 5.2 years (range, 2 to 21
years), 100% had a patent subclavian vein. No patients were
lost to follow-up. All patients now have a fully functional
arm. They all recovered and went back to their usual
occupations or sport activities without restrictions.
Complications. Only one of the 97 patients in group
I experienced a bleeding complication. This was detected
immediately in the early postoperative period by the rou-
tine chest radiograph in the recovery room that showed a
large collection of blood in the apex of the lung. This
patient required re-exploration and hemostasis, and recov-
ered uneventfully. In another two patients, the extrapleural
dissection implemented to resect the first rib accidentally
caused a tear in the pleura that required implanting a chest
tube to re-expand the lungs. These two patients also recov-
ered uneventfully and were discharged to home on the
fourth and fifth day postoperatively.
Lymphocele developed in two more patients in the
extrapleural space that required sclerotherapy by the radi-
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rhuate 3% solution, which was effective.
Seven patients showed postoperative residual stenosis
that required balloon dilation and stent placement: two at
the 24-hour postoperative venogram, four at the 1-week
follow-up ultrasound scan, and one at 6 months. All were
treated successfully with balloon dilation and stents, and all
remain patent up to 14 years later.
The 12 patients who had long obstructions and under-
went transmanubrial extension of the incision with place-
ment of a long saphenous vein patch all remain patent,
without the need for stent placement. All of their incisions
healed properly. Only one patient needed to have the wires
removed later; because of her slender build, the patient
could palpate the wire through her skin, which caused
tenderness.
Of the 17 patients who were initially treated conserva-
tively (group II), only five (29%) had anatomy that made
them operable after thrombolysis. In these five, the axillary
vein inflow to the subclavian vein was 1 cm in diameter. In
three patients we also placed a long saphenous vein patch
that later required balloon dilation and implantation of
endovascular covered stents. Even so, only four of these five
patients had a patent subclavian vein at the end of the year.
We found the conditions in the other 12 group II
patients to be inoperable because during the wait between
the implementation of their thrombolytic therapy and their
referral for surgery, their vein had reoccluded completely,
with extensive fibrosis into the axillary vein. Most of their
circulation was being accomplished by collateral branches
that had formed a network of veins around the shoulder
and subclavicular area. These 12 patients have remained
partially disabled, with chronic edema, aching, and pain.
Five of them use continuous elastic compressive devices to
prevent edema.
DISCUSSION
At the present time, there is no disagreement on the use
of thrombolytic agents as a first step in the treatment of
Paget-Schroetter syndrome. The disagreement among sev-
eral authors14,17,21 comes at what to do after the throm-
bolysis has been completed. There are four option possibil-
ities:
1. Anticoagulant therapy only. This is completely unac-
ceptable as a definitive therapy. It does not address the
extrinsic compression of the vein and leaves the patient
with the same anatomic setting that led to the obstruc-
tion. The patient is left with severe disability, as shown
by Tilney et al,22 Adams et al,9 and Cambell et al,23 who
studied the natural history of Paget-Schroetter. Balloon
angioplasty alone without anatomic decompression is
highly ineffective.4,12,17
2. Decompression with only venolysis,21,24 which involves
removal of the first rib with a scalenectomy and removal
of scar tissue around the vein, also does not address the
intrinsic fibrotic obstruction of the vein itself. It does
not re-establish the normal caliber of the vein and it maybe applicable only in a few cases in which the obstruction
of the vein is not severe.
3. Surgical decompression with intraoperative balloon an-
gioplasty only.14 This approach in the past showed a
high recurrent obstruction rate.17 More recently, better
results have been published,14 but it may be successful
only in cases with mild, short stenosis. It requires intra-
operative fluoroscopy and venography.
4. Decompression, followed by placement of stents. This
approach has been shown to have a significant long-
term failure rate in which the vein will reobstruct or
refibrose at the site of the stent.16 It also involves two
separate interventions, with long-term anticoagulation,
and introduces a foreign device. This is acceptable only
if a patch procedure fails, but is not recommended as a
routine approach.
If we compare the results of immediate surgery with
placement of the vein patch at the narrow segment of the
vein versus these other options, it shows that the patch
technique has superior results. In addition, the option of an
emergent operation during the acute event has the advan-
tages of having only one operation that solves the entire
problem and a single 8-week period of anticoagulation
regimen. No stents are routinely used, no fluoroscopy is
needed, and no foreign material inserted with the accom-
panying uncertain long-term possibility of complications.
On the other hand, stents should not be used as a routine
after decompression because their long-term patency is
unknown, and because even at short-term follow-up,
Kreienberg et al16 demonstrated a patency rate of only 64%
in a small series.
The transaxillary removal of the first rib, reported by
other groups for decompression after the thrombolysis
stage, does not seem to be a satisfactory approach either. It
does not solve the vein stricture. Kunkel and Machleder17
showed that 13 of 35 patients treated in this manner had
residual occlusion. They also showed that balloon plasty
alone, without inlet decompression, was not effective.
Our emergent protocol for treating patients with
Paget-Schroetter syndrome was developed in 1985.5 How-
ever, because the syndrome is rather rarely seen in a stan-
dard vascular or cardiothoracic surgery setting, sufficient
experience is acquired only in tertiary care centers, such as
ours, that receive steady numbers of these patients. Thus,
our institution has long advocated emergent care6 for these
patients.
It is obvious from our study and experience that waiting
weeks to operate to solve the venous obstruction is not
desirable. Implementing immediate care and surgery is the
only chance these patients have to be cured before severe
fibrosis takes place in the affected vein. Total obliteration
renders the condition inoperable and may render the pa-
tient partially disabled for life.23-25 Collateral circulation
will never compensate for the lack of a proper channel of
venous outflow during arm activity. In a bedridden patient
with no or very little physical activity, this collateral circu-
lation may be adequate to prevent edema of the arm at rest;
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are young, with occupations that demand physical exertion
or with intense involvement of the arms in sports. They will
experience swelling and pain after a few minutes of activity.
One very important technical issue in implementing
our operation, actually the key to success, is that the saphe-
nous vein patch placed over the obstructed segment must
extend across the obstruction into a normal vein medially,
going into the innominate vessel as well as distally into the
axillary vein. If this is not accomplished properly, the oper-
ationwill fail and the veinwill reobstruct shortly after surgery.
To prevent this occurrence, the most important step is to
dissect the vein anteriorly behind the sternum (Fig 6), detach-
ing the subclavian vein from the posterior surface of the
sternum and allowing the innominate vein to be mobilized
and pulled into the operative field.
Success of the operation depends on the length of
normal vein medial to the site of the obstruction, where the
vein patch is laid to keep a patent vessel. A sharply curved
clamp always needs to be applied to the innominate vein
beyond the site of the obstruction, allowing the saphenous
vein patch to extend to a normal vessel (Fig 4). The
segment of saphenous vein patch to be used is always short,
only 4 cm. It should be obtained from the upper thigh,
because only at that level is the saphenous vein of sufficient
diameter to provide for a large adequate patch to reconsti-
tute the diameter of the normal subclavian vein.
If there is any doubt about the vein patch extending far
enough medially behind the sternum to maintain adequate
vein caliber or if there is strong doubt about patency of the
vein after the operation, a venogram must be obtained the
morning after surgery, 24 hours after the operation, to
assess the situation. If the vein has reoccluded or is severely
Fig 6. The key to success is the complete mobilization of the
subclavian vein, detaching it anteriorly from the sternum (arrow)
until the vein is easily exposed in the operative field, allowing
sufficient margin for placement of the medial clamp between the
site of the stricture and normal innominate vein.stenotic, this is a clear indication for the interventionalradiologist to perform balloon plasty of the stricture and to
implant a covered stent to solve the problem. The radiolo-
gist needs to use a stent 10 mm in diameter. Only at this
time can stent placement be done safely, because the vein
patch provides a large circumference to dilate that segment
without causing disruption of the suture line. In addition,
the covered stent will seal off any type of potential leak. In
our series, we have never observed any leaks or bleeding
owing to immediate postoperative stent placement.
CONCLUSIONS
Paget-Schroetter syndrome is an acute serious event
and absolutely requires immediate care and, we believe,
prompt surgery. The results are unsatisfactory with the
conservative treatment of thrombolysis, followed by anti-
coagulation, which will not solve the obstructive problem
and leads to reobstruction of the vein. Implementation of
our emergent protocol of care is recommended within the
first 2 weeks after the occurrence to be successful. Late
surgery means commonly no adequate vein channel that
can be patched, dilated, or bypassed.
The use of stents without surgery usually fails because
the subclavian vein is still compressed by the extrinsic
structures of the thoracic inlet, so the stent will be flattened
and crushed by the patient’s arm movement.11-13 The
thoracic inlet must be decompressed first, and all of the
pinching mechanism eliminated, for an endovascular stent
to function properly and prevent reobstruction.
The success rate of this one-time emergent approach to
treat the Paget-Schroetter syndrome seems to render better
and more consistent results than previously published re-
ports. We strongly recommend our protocol for optimal
results with vein patch enlargement of the subclavian vein
and no stent placement whenever possible.
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